Tag: DCIS
DCIS (ductal carcinoma in situ): A non-invasive form of breast cancer in which the cancer cells are confined to milk ducts and have not spread beyond the duct walls to invade the surrounding tissue.
Articles
- Breast cancer types
- DCIS recurrence & survival data
- Ductal breast cancer and DCIS characteristics
- Ductal carcinoma in situ (DCIS) prognosis
- Tumor proliferation, as measured by Ki-67, predicts BC outcomes
- Young breast cancer survivors can reduce risk of recurrence
News
- 12/06/15
- Heavily treated DCIS less likely to progress in the long term
- 03/16/14
- Over 80% of women diagnosed with DCIS or LCIS do not progress
- 01/12/14
- Almost 1-in-3 relapse if no radiation after lumpectomy for DCIS
- 03/13/13
- Radiotherapy significantly reduces recurrence in women with DCIS
- 03/19/12
- Risk of DCIS relapse or progression continues at least 20 years
- 03/17/11
- Radiation after lumpectomy reduces recurrence for DCIS survivors
- 12/11/10
- Radiotherapy substantially reduces additional BC in women with DCIS
- 11/19/10
- Factors predicting upstaging from DCIS to invasive BC at biopsy
- 10/18/10
- Women with DCIS and dense breasts have a higher risk of additional BC
- 03/22/10
- Breast reduction surgery may be combined with lumpectomy for DCIS
Studies
-
Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018
Cite
Bowles EJA, Ramin C, Vo JB, Feigelson HS, Gander JC, Veiga LHS, et al. Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 208:577-587 10.1007/s10549-024-07453-0
-
Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis
Cite
Chen Q, Campbell I, Elwood M, Cavadino A, Aye PS, Tin Tin S. Outcomes from low-risk ductal carcinoma in situ: a systematic review and meta-analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2024; 208:237-251 10.1007/s10549-024-07473-w
-
Survival outcomes after omission of surgery for ductal carcinoma in situ
Cite
Poli EC, Dong W, Shaitelman SF, Tamirisa N, Shen Y, Bedrosian I. Survival outcomes after omission of surgery for ductal carcinoma in situ. npj Breast Cancer. Springer Science and Business Media LLC; 2024; 10 10.1038/s41523-024-00689-5
-
Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade
Cite
O’Leary RL, Duijm LEM, Boersma LJ, van der Sangen MJC, de Munck L, Wesseling J, et al. Invasive recurrence after breast conserving treatment of ductal carcinoma in situ of the breast in the Netherlands: time trends and the association with tumour grade. British Journal of Cancer. Springer Science and Business Media LLC; 2024; 131:852-859 10.1038/s41416-024-02785-6
-
Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome
Cite
Strand SH, Houlahan KE, Branch V, Lynch T, Rivero-Guitiérrez B, Harmon B, et al. Analysis of ductal carcinoma in situ by self-reported race reveals molecular differences related to outcome. Breast Cancer Research. Springer Science and Business Media LLC; 2024; 26 10.1186/s13058-024-01885-8
-
Update on the management of ductal carcinoma in situ of the breast: current approach and future perspectives
Cite
Kanbayashi C, Iwata H. Update on the management of ductal carcinoma in situ of the breast: current approach and future perspectives. Japanese Journal of Clinical Oncology. Oxford University Press (OUP); 2024; 10.1093/jjco/hyae122
-
Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study
Cite
Wang SM, Li Y, Nash A, Ren Y, Thomas SM, Francescatti AB, et al. Disease-specific survival outcomes for patients after locoregional treatment for ductal carcinoma in situ: observational cohort study. British Journal of Surgery. Oxford University Press (OUP); 2024; 111 10.1093/bjs/znae198
-
Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance
Cite
Van Bockstal MR, Wesseling J, Lips EH, Smidt M, Galant C, van Deurzen CHM. Systematic assessment of HER2 status in ductal carcinoma in situ of the breast: a perspective on the potential clinical relevance. Breast Cancer Research. Springer Science and Business Media LLC; 2024; 26 10.1186/s13058-024-01875-w
-
Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ
Cite
Greenwood HI, Maldonado Rodas CK, Freimanis RI, Glencer AC, Miller PN, Mukhtar RA, et al. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ. npj Breast Cancer. Springer Science and Business Media LLC; 2024; 10 10.1038/s41523-024-00677-9
-
Trajectory of Subsequent Breast Cancer Diagnoses in a Diverse Patient Cohort with Breast Atypia
Cite
Limberg JN, Thomas SM, Dalton JC, Ntowe KW, Nash AL, Chiba A, et al. Trajectory of Subsequent Breast Cancer Diagnoses in a Diverse Patient Cohort with Breast Atypia. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2024; 10.1245/s10434-024-15788-7
-
Racial disparities in disease‐specific mortality and surgical management of patients with ductal carcinoma in situ with microinvasion
Cite
Chen JC, Handley D, Elsaid MI, Fisher JL, Owusu‐Brackett N, Azap L, et al. Racial disparities in disease‐specific mortality and surgical management of patients with ductal carcinoma in situ with microinvasion. Journal of Surgical Oncology. Wiley; 2024; 129:1179-1186 10.1002/jso.27625
-
Mammographically and sonographically occult male DCIS seen only on breast MRI
Cite
Osei K, Panigrahi B. Mammographically and sonographically occult male DCIS seen only on breast MRI. Radiology Case Reports. Elsevier BV; 2024; 19:3390-3393 10.1016/j.radcr.2024.05.006
-
Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment
Cite
Delaloge S, Khan SA, Wesseling J, Whelan T. Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment. The Lancet. Elsevier BV; 2024; 10.1016/s0140-6736(24)00425-2
-
Pathological Underestimation of Core Needle Biopsy Risks in Ductal Carcinoma In Situ Breast Cancer Diagnosis: a Predictive Nomogram
Cite
Xie S, Wang Y, Song J, Guo J, Wang X, Cui M. Pathological Underestimation of Core Needle Biopsy Risks in Ductal Carcinoma In Situ Breast Cancer Diagnosis: a Predictive Nomogram. Research Square Platform LLC; 2024; 10.21203/rs.3.rs-4201550/v1
-
Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance
Cite
Wang J, Li B, Luo M, Huang J, Zhang K, Zheng S, et al. Progression from ductal carcinoma in situ to invasive breast cancer: molecular features and clinical significance. Signal Transduction and Targeted Therapy. Springer Science and Business Media LLC; 2024; 9 10.1038/s41392-024-01779-3
-
Cancer Incidence, Type, and Survival After Bariatric Surgery
Cite
Miller JR, Borgert AJ, Fitzsimmons AJ, Mellion KM, Pfeiffer JD, Grover BT. Cancer Incidence, Type, and Survival After Bariatric Surgery. Surgery for Obesity and Related Diseases. Elsevier BV; 2024; 10.1016/j.soard.2024.03.009
-
Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study
Cite
Wright JL, Gray R, Rahbar H, Comstock CE, Tjoe JA, Badve S, et al. Lumpectomy without radiation for ductal carcinoma in situ of the breast: 20-year results from the ECOG-ACRIN E5194 study. npj Breast Cancer. Springer Science and Business Media LLC; 2024; 10 10.1038/s41523-024-00622-w
-
Atypical Ductal Hyperplasia and Lobular In Situ Neoplasm: High-Risk Lesions Challenging Breast Cancer Prevention
Cite
Nicosia L, Mariano L, Pellegrino G, Ferrari F, Pesapane F, Bozzini AC, et al. Atypical Ductal Hyperplasia and Lobular In Situ Neoplasm: High-Risk Lesions Challenging Breast Cancer Prevention. Cancers. MDPI AG; 2024; 16:837 10.3390/cancers16040837
-
Metabolic Syndrome and the Risk of Ductal Carcinoma In Situ of the Breast in the UK Biobank
Cite
Peila R, Rohan TE. Metabolic Syndrome and the Risk of Ductal Carcinoma In Situ of the Breast in the UK Biobank. Cancer Epidemiology, Biomarkers & Prevention. American Association for Cancer Research (AACR); 2024; 33:333-336 10.1158/1055-9965.epi-23-0846
-
Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study
Cite
Mannu GS, Wang Z, Dodwell D, Broggio J, Charman J, Darby SC. Invasive breast cancer and breast cancer death after non-screen detected ductal carcinoma in situ from 1990 to 2018 in England: population based cohort study. BMJ. BMJ; 2024;:e075498 10.1136/bmj-2023-075498
-
Circulating levels of biomarkers and risk of ductal carcinoma in situ of the breast in the UK Biobank study
Cite
Peila R, Rohan TE. Circulating levels of biomarkers and risk of ductal carcinoma in situ of the breast in the UK Biobank study. International Journal of Cancer. Wiley; 2023; 10.1002/ijc.34795
-
Nationwide Analysis of Locoregional Management for Ductal Carcinoma In Situ in Males: An NCDB Analysis of the Surgical Approach to DCIS in Males
Cite
Carter MM, Whitrock JN, Pratt CG, Shaughnessy EA, Meier TM, Barrord MF, et al. Nationwide Analysis of Locoregional Management for Ductal Carcinoma In Situ in Males: An NCDB Analysis of the Surgical Approach to DCIS in Males. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 10.1245/s10434-023-14579-w
-
The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population
Cite
Alaeikhanehshir S, Schmitz RS, van den Belt-Dusebout AW, van Duijnhoven FH, Verschuur E, van Seijen M, et al. The effects of contemporary treatment of DCIS on the risk of developing an ipsilateral invasive Breast cancer (iIBC) in the Dutch population. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07168-8
-
In situ breast cancer surgeries in Sweden: lumpectomy or mastectomy?—a cost-effectiveness analysis over a 30-Year period using Markov model
Cite
Pham PD, Muchadeyi MT, Lindholm L. In situ breast cancer surgeries in Sweden: lumpectomy or mastectomy?—a cost-effectiveness analysis over a 30-Year period using Markov model. Cost Effectiveness and Resource Allocation. Springer Science and Business Media LLC; 2023; 21 10.1186/s12962-023-00495-z
-
Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial
Cite
Kantor O, King TA, Jones A, Glass C, Leonard SJ, Ogayo ER, et al. Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2023; 30:8404-8411 10.1245/s10434-023-14344-z
-
Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study
Cite
Schmitz RSJM, van den Belt-Dusebout AW, Clements K, Ren Y, Cresta C, Timbres J, et al. Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study. BMJ. BMJ; 2023;:e076022 10.1136/bmj-2023-076022
-
Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer–related adverse health events
Cite
Mitchell JM, DeLeire T, Isaacs C. Adherence to hormonal therapy after surgery among older women with ductal carcinoma in situ: Implications for breast cancer–related adverse health events. Cancer. Wiley; 2023; 10.1002/cncr.35009
-
Ipsilateral tumor recurrence risk in women with ductal carcinoma in situ: application of the Van Nuys Prognostic Index and the Memorial Sloan Kettering Cancer Center nomogram
Cite
Hashiba KA, Bahl M. Ipsilateral tumor recurrence risk in women with ductal carcinoma in situ: application of the Van Nuys Prognostic Index and the Memorial Sloan Kettering Cancer Center nomogram. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 202:185-190 10.1007/s10549-023-07036-5
-
Estrogen Receptor-negative Ductal Carcinoma In Situ (DCIS) of the Breast – an Institutional Review of Outcomes
Cite
ZABROCKA E, NEWMAN B, LEVEY G, SWEENEY K, OENTORO J, RYU S, et al. Estrogen Receptor-negative Ductal Carcinoma In Situ (DCIS) of the Breast – an Institutional Review of Outcomes. Anticancer Research. Anticancer Research USA Inc.; 2023; 43:4031-4036 10.21873/anticanres.16591
-
Active Surveillance of Atypical Ductal Hyperplasia of the Breast
Cite
Han LK, Hussain A, Dodelzon K, Ginter PS, Towne WS, Marti JL. Active Surveillance of Atypical Ductal Hyperplasia of the Breast. Clinical Breast Cancer. Elsevier BV; 2023; 23:649-657 10.1016/j.clbc.2023.05.008
-
Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact
Cite
Schandiz H, Park D, Kaiser YL, Lyngra M, Talleraas IS, Geisler J, et al. Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 201:329-338 10.1007/s10549-023-07016-9
-
Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis
Cite
Ploumen RAW, Claassens EL, Kooreman LFS, Keymeulen KBMI, van Kats MACE, Gommers S, et al. Pathologic complete response of ductal carcinoma in situ to neoadjuvant systemic therapy in HER2-positive invasive breast cancer patients: a nationwide analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2023; 10.1007/s10549-023-07012-z
-
Predicting Upgrade of Ductal Carcinoma In Situ to Invasive Breast Cancer at Surgery With Ultrafast Imaging
Cite
Miceli R, Gao Y, Qian K, Heller SL. Predicting Upgrade of Ductal Carcinoma In Situ to Invasive Breast Cancer at Surgery With Ultrafast Imaging. American Journal of Roentgenology. American Roentgen Ray Society; 2023; 221:34-43 10.2214/ajr.22.28698
-
Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study
Cite
Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, et al. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2023; 41:3116-3121 10.1200/jco.22.02900
-
Surgical Treatments for Ductal Carcinoma In Situ (DCIS) in Elderly Patients
Cite
BUONOMO OC, PELLICCIARO M, MATERAZZO M, BERARDI S, GIGLIOTTI PE, CASPI J, et al. Surgical Treatments for Ductal Carcinoma In Situ (DCIS) in Elderly Patients. Anticancer Research. Anticancer Research USA Inc.; 2023; 43:1555-1562 10.21873/anticanres.16305
-
Oncological outcomes after simple and skin-sparing mastectomy of ductal carcinoma in situ: A register-based cohort study of 576 Norwegian women
Cite
Skjerven HK, Myklebust EM, Korvald C, Porojnicu AC, Kaaresen R, Hofvind S, et al. Oncological outcomes after simple and skin-sparing mastectomy of ductal carcinoma in situ: A register-based cohort study of 576 Norwegian women. European Journal of Surgical Oncology. Elsevier BV; 2023; 49:575-582 10.1016/j.ejso.2022.11.594
-
Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea
Cite
Kim D, Oh J, Seok J, Lee HS, Jeon S, Yoon CI. Risk of Secondary Cancer after Adjuvant Tamoxifen Treatment for Ductal Carcinoma In Situ: A Nationwide Cohort Study in South Korea. Diagnostics. MDPI AG; 2023; 13:792 10.3390/diagnostics13040792
-
The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)—results from the UK Sloane Project
Cite
Shaaban AM, Hilton B, Clements K, Dodwell D, Sharma N, Kirwan C, et al. The presentation, management and outcome of patients with ductal carcinoma in situ (DCIS) with microinvasion (invasion ≤1 mm in size)—results from the UK Sloane Project. British Journal of Cancer. Springer Science and Business Media LLC; 2022; 127:2125-2132 10.1038/s41416-022-01983-4
-
Is palpable DCIS more aggressive than screen-detected DCIS?
Cite
Balac N, Tungate RM, Jeong YJ, MacDonald H, Tung L, Schechter NR, et al. Is palpable DCIS more aggressive than screen-detected DCIS?. Surgery Open Science. Elsevier BV; 2022; 10.1016/j.sopen.2022.12.002
-
Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence
Cite
O’Keefe TJ, Chau H, Harismendy O, Wallace AM. Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence. Surgery. Elsevier BV; 2022; 10.1016/j.surg.2022.10.009
-
Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ
Cite
Tesch ME, Rosenberg SM, Collins LC, Wong JS, Dominici L, Ruddy KJ, et al. Clinicopathologic Features, Treatment Patterns, and Disease Outcomes in a Modern, Prospective Cohort of Young Women Diagnosed with Ductal Carcinoma In Situ. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022; 29:8048-8057 10.1245/s10434-022-12361-y
-
Risk of Breast Cancer in Selected Women With Atypical Ductal Hyperplasia Who do not Undergo Surgical Excision
Cite
Kilgore LJ, Yi M, Bevers T, Coyne R, Marita L, Lane D, et al. Risk of Breast Cancer in Selected Women With Atypical Ductal Hyperplasia Who do not Undergo Surgical Excision. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2022; 276:e932-e936 10.1097/sla.0000000000004849
-
Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center
Cite
Nicosia L, Lissidini G, Sargenti M, Bozzini AC, Farante G, Vila J, et al. Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 196:371-377 10.1007/s10549-022-06689-y
-
Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS
Cite
Nakhlis F, Katlin FD, Grossmith SC, DiPasquale A, Harrison BT, Schnitt SJ, et al. Presence of Non-classic LCIS Is Not a Contraindication to Breast Conservation in Patients with Concomitant Invasive Breast Cancer or DCIS. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2022; 10.1245/s10434-022-12066-2
-
Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma
Cite
Nakayama S, Masuda H, Miura S, Kuwayama T, Hashimoto R, Taruno K, et al. Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma. Breast Cancer. Springer Science and Business Media LLC; 2022; 29:610-617 10.1007/s12282-022-01338-0
-
Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer
Cite
Lips EH, Kumar T, Megalios A, Visser LL, Sheinman M, Fortunato A, et al. Genomic analysis defines clonal relationships of ductal carcinoma in situ and recurrent invasive breast cancer. Nature Genetics. Springer Science and Business Media LLC; 2022; 54:850-860 10.1038/s41588-022-01082-3
-
Low-dose tamoxifen for breast cancer prevention in patients with ductal carcinoma in situ (DCIS) and atypical lesions: A real-world experience.
Cite
Patel R, Jin C, Tiersten A. Low-dose tamoxifen for breast cancer prevention in patients with ductal carcinoma in situ (DCIS) and atypical lesions: A real-world experience.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022; 40:e12537-e12537 10.1200/jco.2022.40.16_suppl.e12537
-
Is conservative management of ductal carcinoma in situ risky?
Cite
Zheng L, Gökmen-Polar Y, Badve SS. Is conservative management of ductal carcinoma in situ risky?. npj Breast Cancer. Springer Science and Business Media LLC; 2022; 8 10.1038/s41523-022-00420-2
-
Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast
Cite
Jia H, Zhao P, Chen Z, Wang G, Dong X, Xing X, et al. Clinicopathological characteristics and prognostic analysis of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ (DCIS) and DCIS with microinvasion (DCIS-Mi) of the breast. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 193:111-120 10.1007/s10549-022-06553-z
-
Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease
Cite
DeCensi A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, Caviglia S, Avino F, et al. Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. Clinical Cancer Research. American Association for Cancer Research (AACR); 2021; 27:3576-3583 10.1158/1078-0432.ccr-20-4213
-
Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen
Cite
Bychkovsky B, Laws A, Katlin F, Hans M, Knust Graichen M, Pace LE, et al. Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06577-5
-
Diallyl Trisulfide Induces Apoptosis in Breast Ductal Carcinoma In Situ Derived and Minimally Invasive Breast Cancer Cells
Cite
Stan SD, Abtahi M. Diallyl Trisulfide Induces Apoptosis in Breast Ductal Carcinoma In Situ Derived and Minimally Invasive Breast Cancer Cells. Nutrients. MDPI AG; 2022; 14:1455 10.3390/nu14071455
-
Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy
Cite
Yang L, Shen M, Qiu Y, Tingting T, Bu H. Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy. The Breast. Elsevier BV; 2022; 10.1016/j.breast.2022.03.019
-
Abstract P1-22-06: A longitudinal cohort study of outcomes in 311 women with unresected ductal carcinoma in situ detected through the English breast screening programme
Cite
Clements K, Maxwell A, Hilton B, Wallis M, Kirwan C, Stobart H, et al. Abstract P1-22-06: A longitudinal cohort study of outcomes in 311 women with unresected ductal carcinoma in situ detected through the English breast screening programme. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P1-22-06-P1-22-06 10.1158/1538-7445.sabcs21-p1-22-06
-
Abstract P3-12-36: The diagnosis and prognosis of ductal carcinoma in situ (DCIS) with microinvasion - Results from the United Kingdom Sloane project
Cite
Shaaban AM, Hilton B, Clements K, Dodwell D, Sharma N, Kirwan C, et al. Abstract P3-12-36: The diagnosis and prognosis of ductal carcinoma in situ (DCIS) with microinvasion - Results from the United Kingdom Sloane project. Cancer Research. American Association for Cancer Research (AACR); 2022; 82:P3-12-36-P3-12-36 10.1158/1538-7445.sabcs21-p3-12-36
-
Alcohol consumption, smoking, and invasive breast cancer risk after ductal carcinoma in situ
Cite
Jordahl KM, Malone KE, Baglia ML, Flanagan MR, Tang MC, Porter PL, et al. Alcohol consumption, smoking, and invasive breast cancer risk after ductal carcinoma in situ. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-022-06573-9
-
Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy
Cite
Zhou H, Yu J, Wang X, Shen K, Ye J, Chen X. Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy. Scientific Reports. Springer Science and Business Media LLC; 2022; 12 10.1038/s41598-022-06206-7
-
Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy
Cite
Rodin D, Sutradhar R, Nofech-Mozes S, Gu S, Faught N, Hahn E, et al. Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2022; 10.1007/s10549-021-06488-x
-
The Effect of Smoking on Progression from Ductal Carcinoma In Situ to Invasive Ductal Breast Carcinoma: A Retrospective Study
Cite
TAKADA K, KASHIWAGI S, ASANO Y, GOTO W, MORISAKI T, SHIBUTANI M, et al. The Effect of Smoking on Progression from Ductal Carcinoma In Situ to Invasive Ductal Breast Carcinoma: A Retrospective Study. Anticancer Research. Anticancer Research USA Inc.; 2021; 42:311-320 10.21873/anticanres.15487
-
Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer
Cite
Park KW, Kim SW, Han H, Park M, Han B, Ko EY, et al. Ductal carcinoma in situ: a risk prediction model for the underestimation of invasive breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2022; 8 10.1038/s41523-021-00364-z
-
Thyroid Hormones and Morphological Features of Primary Breast Cancer
Cite
MEIROVITZ A, NISMAN B, ALLWEIS TM, CARMON E, KADOURI L, MALY B, et al. Thyroid Hormones and Morphological Features of Primary Breast Cancer. Anticancer Research. Anticancer Research USA Inc.; 2021; 42:253-261 10.21873/anticanres.15480
-
Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study
Cite
Maxwell AJ, Hilton B, Clements K, Dodwell D, Dulson-Cox J, Kearins O, et al. Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study. The Breast. Elsevier BV; 2022; 61:145-155 10.1016/j.breast.2022.01.001
-
Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study
Cite
Tanaka K, Masuda N, Hayashi N, Sagara Y, Hara F, Kadoya T, et al. Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study. Breast Cancer. Springer Science and Business Media LLC; 2021; 28:896-903 10.1007/s12282-021-01225-0
-
Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor
Cite
Hwang K, Suh YJ, Park C, Lee YJ, Kim JY, Jung JH, et al. Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor. The Oncologist. Wiley; 2021; 26 10.1002/onco.13938
-
Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804
Cite
McCormick B, Winter KA, Woodward W, Kuerer HM, Sneige N, Rakovitch E, et al. Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2021;:JCO.21.01083 10.1200/jco.21.01083
-
Evaluation of the Effects of Different Dietary Patterns on Breast Cancer: Monitoring Circulating Tumor Cells
Cite
Wang X, Liu X, Jia Z, Zhang Y, Wang S, Zhang H. Evaluation of the Effects of Different Dietary Patterns on Breast Cancer: Monitoring Circulating Tumor Cells. Foods. MDPI AG; 2021; 10:2223 10.3390/foods10092223
-
Prognostic and predictive value of HER2 expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS randomized trial.
Cite
Thorat MA, Levey PM, Jones JL, Pinder SE, Bundred NJ, Fentiman IS, et al. Prognostic and predictive value of HER2 expression in ductal carcinoma in situ: Results from the UK/ANZ DCIS randomized trial.. Clinical Cancer Research. American Association for Cancer Research (AACR); 2021;:clincanres.1239.2021 10.1158/1078-0432.ccr-21-1239
-
Let Us Move Out of Plato’s Cave: The Greater Reality of DCIS
Cite
Kuhl CK. Let Us Move Out of Plato’s Cave: The Greater Reality of DCIS. Radiology. Radiological Society of North America (RSNA); 2021;:211596 10.1148/radiol.2021211596
-
Does margin width impact breast cancer recurrence rates in women with breast conserving surgery for ductal carcinoma in situ?
Cite
Livingston-Rosanoff D, Trentham-Dietz A, Hampton JM, Newcomb PA, Wilke LG. Does margin width impact breast cancer recurrence rates in women with breast conserving surgery for ductal carcinoma in situ?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2021; 10.1007/s10549-021-06278-5
-
Can breast cancer be stopped? Modifiable risk factors of breast cancer among women with a prior benign or premalignant lesion
Cite
Lilleborge M, Falk RS, Sørlie T, Ursin G, Hofvind S. Can breast cancer be stopped? Modifiable risk factors of breast cancer among women with a prior benign or premalignant lesion. International Journal of Cancer. Wiley; 2021; 10.1002/ijc.33680
-
Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients
Cite
Stanton SE, Gad E, Ramos E, Corulli L, Annis J, Childs J, et al. Tumor-associated autoantibodies from mouse breast cancer models are found in serum of breast cancer patients. npj Breast Cancer. Springer Science and Business Media LLC; 2021; 7 10.1038/s41523-021-00257-1
-
Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients
Cite
Cutuli B, Lemanski C, De Lafontan B, Chauvet M, De Lara CT, Mege A, et al. Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients. Clinical Breast Cancer. Elsevier BV; 2020; 20:e164-e172 10.1016/j.clbc.2019.08.002
-
The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ
Cite
Miligy IM, Toss MS, Shiino S, Oni G, Syed BM, Khout H, et al. The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 123:1513-1520 10.1038/s41416-020-1023-3
-
Melatonin inhibits cell proliferation in a rat model of breast hyperplasia by mediating the PTEN/AKT pathway
Cite
Zhang X, Niu Y, Huang Y. Melatonin inhibits cell proliferation in a rat model of breast hyperplasia by mediating the PTEN/AKT pathway. Oncology Reports. Spandidos Publications; 2021; 45 10.3892/or.2021.8017
-
Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project
Cite
Shaaban AM, Hilton B, Clements K, Provenzano E, Cheung S, Wallis MG, et al. Pathological features of 11,337 patients with primary ductal carcinoma in situ (DCIS) and subsequent events: results from the UK Sloane Project. British Journal of Cancer. Springer Science and Business Media LLC; 2020; 124:1009-1017 10.1038/s41416-020-01152-5
-
Long-term survival comparison of repeated breast conserving surgery vs. mastectomy for DCIS patients with ipsilateral breast tumor recurrence: A real-world longitudinal study
Cite
Li Q, Wang K, Yang L, Wu Q, Zhu W, Li Z, et al. Long-term survival comparison of repeated breast conserving surgery vs. mastectomy for DCIS patients with ipsilateral breast tumor recurrence: A real-world longitudinal study. Clinical Breast Cancer. Elsevier BV; 2021; 10.1016/j.clbc.2021.02.012
-
Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ
Cite
Sestak I, Cuzick J, Bonanni B, Bundred N, Levy C, Loib S, et al. Abstract GS2-02: 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ. General Session Abstracts. American Association for Cancer Research; 2021; 10.1158/1538-7445.sabcs20-gs2-02
-
Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ
Cite
Takada K, Kashiwagi S, Asano Y, Goto W, Morisaki T, Takahashi K, et al. Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ. BMC Cancer. Springer Science and Business Media LLC; 2020; 20 10.1186/s12885-020-07001-1
-
21-Gene Assay and Breast Cancer Mortality in Ductal Carcinoma in Situ
Cite
Rakovitch E, Sutradhar R, Nofech-Mozes S, Gu S, Fong C, Hanna W, et al. 21-Gene Assay and Breast Cancer Mortality in Ductal Carcinoma in Situ. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2020; 10.1093/jnci/djaa179
-
Relationship Between Proliferative Breast Lesions and Breast Cancer Risk Factors
Cite
Toktaş O, Elasan S, İliklerden ÜH, Erten R, Karayil AR, Özdemir A, et al. Relationship Between Proliferative Breast Lesions and Breast Cancer Risk Factors. European Journal of Breast Health. Galenos Yayinevi; 2021; 17:15-20 10.4274/ejbh.2020.5713
-
Clinical characteristics of breast ductal carcinoma in situ with microinvasion: a narrative review
Cite
Zheng J, Yu J, Zhou T. Clinical characteristics of breast ductal carcinoma in situ with microinvasion: a narrative review. Journal of International Medical Research. SAGE Publications; 2020; 48:030006052096930 10.1177/0300060520969304
-
Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer
Cite
Giardiello D, Kramer I, Hooning MJ, Hauptmann M, Lips EH, Sawyer E, et al. Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. npj Breast Cancer. Springer Science and Business Media LLC; 2020; 6 10.1038/s41523-020-00202-8
-
A medicare-based comparative mortality analysis of active surveillance in older women with DCIS
Cite
Akushevich I, Yashkin AP, Greenup RA, Hwang ES. A medicare-based comparative mortality analysis of active surveillance in older women with DCIS. npj Breast Cancer. Springer Science and Business Media LLC; 2020; 6 10.1038/s41523-020-00199-0
-
Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study
Cite
Mukama T, Fallah M, Brenner H, Xu X, Sundquist K, Sundquist J, et al. Risk of invasive breast cancer in relatives of patients with breast carcinoma in situ: a prospective cohort study. BMC Medicine. Springer Science and Business Media LLC; 2020; 18 10.1186/s12916-020-01772-x
-
Risk of subsequent in situ and invasive lesions after a primary diagnosis of ductal carcinoma in situ with follow-up time up to 28 years
Cite
Van Seijen M, Lips E, Fu L, Groen E, van Duijnhoven F, Thompson A, et al. Risk of subsequent in situ and invasive lesions after a primary diagnosis of ductal carcinoma in situ with follow-up time up to 28 years. European Journal of Cancer. Elsevier BV; 2020; 138:S10-S11 10.1016/s0959-8049(20)30551-7
-
Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer
Cite
Giannakeas V, Sopik V, Narod SA. Association of a Diagnosis of Ductal Carcinoma In Situ With Death From Breast Cancer. JAMA Network Open. American Medical Association (AMA); 2020; 3:e2017124 10.1001/jamanetworkopen.2020.17124
-
Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma
Cite
Lee J, Jung JH, Kim WW, Park CS, Lee RK, Kim HJ, et al. Efficacy of breast MRI for surgical decision in patients with breast cancer: ductal carcinoma in situ versus invasive ductal carcinoma. BMC Cancer. Springer Science and Business Media LLC; 2020; 20 10.1186/s12885-020-07443-7
-
Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer
Cite
Minami CA, Kantor O, Weiss A, Nakhlis F, King TA, Mittendorf EA. Association Between Time to Operation and Pathologic Stage in Ductal Carcinoma in Situ and Early-Stage Hormone Receptor-Positive Breast Cancer. Journal of the American College of Surgeons. Elsevier BV; 2020; 231:434-447.e2 10.1016/j.jamcollsurg.2020.06.021
-
Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study
Cite
Mannu GS, Wang Z, Broggio J, Charman J, Cheung S, Kearins O, et al. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study. BMJ. BMJ; 2020;:m1570 10.1136/bmj.m1570
-
Lumpectomy Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact
Cite
Schnitt SJ, Moran MS, Giuliano AE. Lumpectomy Margins for Invasive Breast Cancer and Ductal Carcinoma in Situ: Current Guideline Recommendations, Their Implications, and Impact. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2020; 38:2240-2245 10.1200/jco.19.03213
-
Treatment of Ductal Carcinoma In Situ: Considerations for Tailoring Therapy in the Contemporary Era
Cite
Mamtani A, Van Zee KJ. Treatment of Ductal Carcinoma In Situ: Considerations for Tailoring Therapy in the Contemporary Era. Current Breast Cancer Reports. Springer Science and Business Media LLC; 2020; 12:98-106 10.1007/s12609-020-00360-5
-
Abstract P6-15-07: Impact of increased mammary adiposity on DCIS progression
Cite
Almekinders MMM, Schaapveld M, Thijssen B, Hofland I, Mertz M, Peters D, et al. Abstract P6-15-07: Impact of increased mammary adiposity on DCIS progression. Poster Session Abstracts. American Association for Cancer Research; 2020; 10.1158/1538-7445.sabcs19-p6-15-07
-
Ductal Carcinoma In Situ Progression in Dog Model of Breast Cancer
Cite
Mohammed S, Utturkar S, Lee M, Yang H, Cui Z, Atallah Lanman N, et al. Ductal Carcinoma In Situ Progression in Dog Model of Breast Cancer. Cancers. MDPI AG; 2020; 12:418 10.3390/cancers12020418
-
Epidemiologic risk factors for in situ and invasive ductal breast cancer among regularly screened postmenopausal women by grade in the Cancer Prevention Study-II Nutrition Cohort
Cite
Puvanesarajah S, Gapstur SM, Gansler T, Sherman ME, Patel AV, Gaudet MM. Epidemiologic risk factors for in situ and invasive ductal breast cancer among regularly screened postmenopausal women by grade in the Cancer Prevention Study-II Nutrition Cohort. Cancer Causes & Control. Springer Science and Business Media LLC; 2019; 31:95-103 10.1007/s10552-019-01253-4
-
Risk factors for estrogen receptor positive ductal carcinoma in situ of the breast in African American women
Cite
Bertrand KA, Bethea TN, Rosenberg L, Bandera EV, Khoury T, Troester MA, et al. Risk factors for estrogen receptor positive ductal carcinoma in situ of the breast in African American women. The Breast. Elsevier BV; 2020; 49:108-114 10.1016/j.breast.2019.10.009
-
Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma
Cite
Lamb LR, Lehman CD, Oseni TO, Bahl M. Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma. Academic Radiology. Elsevier BV; 2020; 27:1394-1399 10.1016/j.acra.2019.09.025
-
Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ
Cite
Hung P, Wang S, Killelea BK, Mougalian SS, Evans SB, Sedghi T, et al. Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ. JNCI Cancer Spectrum. Oxford University Press (OUP); 2019; 3 10.1093/jncics/pkz052
-
Breast Density in a Contemporary Cohort of Women With Ductal Carcinoma In Situ (DCIS)
Cite
Gooch JC, Chun J, Kaplowitz E, Kurz E, Guth A, Lee J, et al. Breast Density in a Contemporary Cohort of Women With Ductal Carcinoma In Situ (DCIS). Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 26:3472-3477 10.1245/s10434-019-07479-5
-
Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer
Cite
Ward WH, DeMora L, Handorf E, Sigurdson ER, Ross EA, Daly JM, et al. Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2019; 27:386-396 10.1245/s10434-019-07844-4
-
Medication Use to Reduce Risk of Breast Cancer
Cite
Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, et al. Medication Use to Reduce Risk of Breast Cancer. JAMA. American Medical Association (AMA); 2019; 322:857 10.1001/jama.2019.11885
-
Ductal carcinoma in situ: to treat or not to treat, that is the question
Cite
van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. British Journal of Cancer. Springer Science and Business Media LLC; 2019; 121:285-292 10.1038/s41416-019-0478-6
-
Risk of breast cancer by prior screening results among women participating in BreastScreen Norway
Cite
Lilleborge M, Falk RS, Russnes H, Sauer T, Ursin G, Hofvind S. Risk of breast cancer by prior screening results among women participating in BreastScreen Norway. Cancer. Wiley; 2019; 125:3330-3337 10.1002/cncr.32330
-
Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification
Cite
Horimoto Y, Terao T, Tsutsumi Y, Tanabe M, Mogushi K, Hlaing MT, et al. Estrogen Receptor-positive Ductal Carcinoma In Situ Frequently Overexpresses HER2 Protein Without Gene Amplification. The American Journal of Surgical Pathology. Ovid Technologies (Wolters Kluwer Health); 2019; 43:1221-1228 10.1097/pas.0000000000001300
-
Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ
Cite
Liu Y, West R, Weber JD, Colditz GA. Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ. Cancer. Wiley; 2019; 125:3225-3233 10.1002/cncr.32200
-
The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution
Cite
Miligy IM, Toss MS, Gorringe KL, Lee AHS, Ellis IO, Green AR, et al. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution. British Journal of Cancer. Springer Science and Business Media LLC; 2019; 120:1075-1082 10.1038/s41416-019-0436-3
-
Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses
Cite
Visser LL, Groen EJ, van Leeuwen FE, Lips EH, Schmidt MK, Wesseling J. Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2019; 28:835-845 10.1158/1055-9965.epi-18-0976
-
Abstract P5-18-04: HER2 overexpression in ductal carcinoma in situ: A biomarker for risk stratification and therapeutic implication
Cite
Yin J, Gascard P, Last B, Singh M, Tlsty T, Tjoe J. Abstract P5-18-04: HER2 overexpression in ductal carcinoma in situ: A biomarker for risk stratification and therapeutic implication. Poster Session Abstracts. American Association for Cancer Research; 2019; 10.1158/1538-7445.sabcs18-p5-18-04
-
Male DCIS diagnosed after use of over-the-counter hormonal supplement
Cite
Agbroko S, Rojas K, Manasseh D, Borgen P. Male DCIS diagnosed after use of over-the-counter hormonal supplement. International Journal of Surgery Case Reports. Elsevier BV; 2019; 57:60-62 10.1016/j.ijscr.2019.02.028
-
Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study
Cite
Williams LA, Casbas-Hernandez P, Nichols HB, Tse CK, Allott EH, Carey LA, et al. Risk factors for Luminal A ductal carcinoma in situ (DCIS) and invasive breast cancer in the Carolina Breast Cancer Study. PLOS ONE. Public Library of Science (PLoS); 2019; 14:e0211488 10.1371/journal.pone.0211488
-
Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?
Cite
Coopey SB, Kartal K, Li C, Yala A, Barzilay R, Faulkner HR, et al. Atypical ductal hyperplasia in men with gynecomastia: what is their breast cancer risk?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2019; 175:1-4 10.1007/s10549-018-05117-4
-
No Ink on Ductal Carcinoma In Situ: A Single Centre Experience
Cite
FREGATTI P, GIPPONI M, DEPAOLI F, MURELLI F, GUENZI M, BONZANO E, et al. No Ink on Ductal Carcinoma In Situ: A Single Centre Experience. Anticancer Research. Anticancer Research USA Inc.; 2018; 39:459-466 10.21873/anticanres.13134
-
The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women’s characteristics: is it the same?
Cite
Théberge I, Vandal N, Guertin M, Perron L. The mammography screening detection of ductal carcinoma in situ and invasive breast cancer according to women’s characteristics: is it the same?. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 174:525-535 10.1007/s10549-018-05095-7
-
Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens
Cite
Rageth CJ, Rubenov R, Bronz C, Dietrich D, Tausch C, Rodewald A, et al. Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens. Breast Cancer. Springer Science and Business Media LLC; 2018; 26:452-458 10.1007/s12282-018-00943-2
-
Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study
Cite
Ozkaya Akagunduz O, Ergen A, Erpolat P, Gultekin M, Akkus Yildirim B, Parvizi M, et al. Local recurrence outcomes after breast conserving surgery and adjuvant radiotherapy in ductal carcinoma in situ of the breast and a comparison with ECOG E5194 study. The Breast. Elsevier BV; 2018; 42:10-14 10.1016/j.breast.2018.08.094
-
Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified?
Cite
Sorrentino L, Sartani A, Bossi D, Amadori R, Nebuloni M, Truffi M, et al. Sentinel node biopsy in ductal carcinoma in situ of the breast: Never justified?. The Breast Journal. Wiley; 2017; 24:325-333 10.1111/tbj.12928
-
Cancer Outcomes in DCIS Patients Without Locoregional Treatment
Cite
Ryser MD, Weaver DL, Zhao F, Worni M, Grimm LJ, Gulati R, et al. Cancer Outcomes in DCIS Patients Without Locoregional Treatment. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2019; 111:952-960 10.1093/jnci/djy220
-
Surgical upgrade rate of breast atypia to malignancy: An academic center's experience and validation of a predictive model
Cite
Linsk A, Mehta TS, Dialani V, Brook A, Chadashvili T, Houlihan MJ, et al. Surgical upgrade rate of breast atypia to malignancy: An academic center's experience and validation of a predictive model. The Breast Journal. Wiley; 2017; 24:115-119 10.1111/tbj.12885
-
Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy
Cite
Giannakeas V, Sopik V, Narod SA. Association of Radiotherapy With Survival in Women Treated for Ductal Carcinoma In Situ With Lumpectomy or Mastectomy. JAMA Network Open. American Medical Association (AMA); 2018; 1:e181100 10.1001/jamanetworkopen.2018.1100
-
Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study
Cite
Sanft T, Usiskin I, Harrigan M, Cartmel B, Lu L, Li F, et al. Randomized controlled trial of weight loss versus usual care on telomere length in women with breast cancer: the lifestyle, exercise, and nutrition (LEAN) study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 172:105-112 10.1007/s10549-018-4895-7
-
Breast cancer–related deaths according to grade in ductal carcinoma in situ: A Dutch population–based study on patients diagnosed between 1999 and 2012
Cite
van Maaren M, Lagendijk M, Tilanus-Linthorst M, de Munck L, Pijnappel R, Schmidt M, et al. Breast cancer–related deaths according to grade in ductal carcinoma in situ: A Dutch population–based study on patients diagnosed between 1999 and 2012. European Journal of Cancer. Elsevier BV; 2018; 101:134-142 10.1016/j.ejca.2018.07.003
-
Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile
Cite
Takahashi S, Thike AA, Koh VCY, Sasano H, Tan PH. Triple-negative and HER2 positive ductal carcinoma in situ of the breast: characteristics, behavior, and biomarker profile. Virchows Archiv. Springer Science and Business Media LLC; 2018; 473:275-283 10.1007/s00428-018-2416-z
-
Estrogen-receptor status and risk of contralateral breast cancer following DCIS
Cite
Stout NK, Cronin AM, Uno H, Ozanne EM, Hassett MJ, Frank ES, et al. Estrogen-receptor status and risk of contralateral breast cancer following DCIS. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 171:777-781 10.1007/s10549-018-4860-5
-
Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ—A Nested Case–Control Study
Cite
Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, et al. Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ—A Nested Case–Control Study. Clinical Cancer Research. American Association for Cancer Research (AACR); 2018; 24:3593-3601 10.1158/1078-0432.ccr-18-0201
-
Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia
Cite
Degnim AC, Winham SJ, Frank RD, Pankratz VS, Dupont WD, Vierkant RA, et al. Model for Predicting Breast Cancer Risk in Women With Atypical Hyperplasia. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018; 36:1840-1846 10.1200/jco.2017.75.9480
-
The Impact of Hormonal Contraceptives on Breast Cancer Pathology
Cite
Dorchak JA, Maria S, Guarinoni JL, Duensing A, Somiari S, Cavanaugh J, et al. The Impact of Hormonal Contraceptives on Breast Cancer Pathology. Hormones and Cancer. Springer Science and Business Media LLC; 2018; 9:240-253 10.1007/s12672-018-0332-y
-
Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis
Cite
De Lorenzi F, Di Bella J, Maisonneuve P, Rotmensz N, Corso G, Orecchia R, et al. Oncoplastic breast surgery for the management of ductal carcinoma in situ (DCIS): is it oncologically safe? A retrospective cohort analysis. European Journal of Surgical Oncology. Elsevier BV; 2018; 44:957-962 10.1016/j.ejso.2018.04.015
-
Do All Positive Margins in Breast Cancer Patients Undergoing a Partial Mastectomy Need to Be Resected?
Cite
Chagpar AB, Tsangaris TN, Lannin DR. Do All Positive Margins in Breast Cancer Patients Undergoing a Partial Mastectomy Need to Be Resected?. Journal of the American College of Surgeons. Elsevier BV; 2018; 227:13-21 10.1016/j.jamcollsurg.2018.03.003
-
Abstract GS5-08: A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS)
Cite
Wärnberg F, Garmo H, Folkvaljon Y, Holmberg L, Karlsson P, Sandelin K, et al. Abstract GS5-08: A validation of DCIS biological risk profile in a randomised study for radiation therapy with 20 year follow-up (SweDCIS). General Session Abstracts. American Association for Cancer Research; 2018; 10.1158/1538-7445.sabcs17-gs5-08
-
Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database
Cite
Hwang K, Kim E, Jung SH, Lee ES, Kim SI, Lee S, et al. Tamoxifen therapy improves overall survival in luminal A subtype of ductal carcinoma in situ: a study based on nationwide Korean Breast Cancer Registry database. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2018; 169:311-322 10.1007/s10549-018-4681-6
-
Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy
Cite
Muhsen S, Barrio AV, Miller M, Olcese C, Patil S, Morrow M, et al. Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:3888-3895 10.1245/s10434-017-6043-8
-
Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Cite
Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2017; 35:561-564 10.1200/jco.2016.71.0947
-
The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study
Cite
Holm-Rasmussen EV, Jensen M, Balslev E, Kroman N, Tvedskov TF. The use of sentinel lymph node biopsy in the treatment of breast ductal carcinoma in situ: A Danish population-based study. European Journal of Cancer. Elsevier BV; 2017; 87:1-9 10.1016/j.ejca.2017.09.037
-
Personal history of proliferative breast disease with atypia and risk of multifocal breast cancer
Cite
Nutter EL, Weiss JE, Marotti JD, Barth RJ, Eliassen MS, Goodrich ME, et al. Personal history of proliferative breast disease with atypia and risk of multifocal breast cancer. Cancer. Wiley; 2017; 124:1350-1357 10.1002/cncr.31202
-
Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ
Cite
Shurell E, Olcese C, Patil S, McCormick B, Van Zee KJ, Pilewskie ML. Delay in radiotherapy is associated with an increased risk of disease recurrence in women with ductal carcinoma in situ. Cancer. Wiley; 2017; 124:46-54 10.1002/cncr.30972
-
Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study
Cite
Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, et al. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2017; 186:1329-1340 10.1093/aje/kwx206
-
Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ
Cite
Sopik V, Sun P, Narod SA. Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 167:787-795 10.1007/s10549-017-4572-2
-
Breast Cancer Survival is Improved When DCIS Accompanies Invasive Ductal Carcinoma
Cite
Kole A, Park H, Johnson S, Kelly J, Patel A. Breast Cancer Survival is Improved When DCIS Accompanies Invasive Ductal Carcinoma. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2017; 99:E25 10.1016/j.ijrobp.2017.06.651
-
The diagnostic challenge of low-grade ductal carcinoma in situ
Cite
Onega T, Weaver DL, Frederick PD, Allison KH, Tosteson AN, Carney PA, et al. The diagnostic challenge of low-grade ductal carcinoma in situ. European Journal of Cancer. Elsevier BV; 2017; 80:39-47 10.1016/j.ejca.2017.04.013
-
Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy
Cite
Moran MS, Zhao Y, Ma S, Kirova Y, Fourquet A, Chen P, et al. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy. JAMA Oncology. American Medical Association (AMA); 2017; 3:1060 10.1001/jamaoncol.2016.6948
-
Risk of death from breast cancer after treatment for ductal carcinoma in situ
Cite
Wadsten C, Garmo H, Fredriksson I, Sund M, Wärnberg F. Risk of death from breast cancer after treatment for ductal carcinoma in situ. British Journal of Surgery. Oxford University Press (OUP); 2017; 104:1506-1513 10.1002/bjs.10589
-
Trends in Treatment Patterns and Clinical Outcomes in Young Women Diagnosed With Ductal Carcinoma In Situ
Cite
Park HL, Chang J, Lal G, Lal K, Ziogas A, Anton-Culver H. Trends in Treatment Patterns and Clinical Outcomes in Young Women Diagnosed With Ductal Carcinoma In Situ. Clinical Breast Cancer. Elsevier BV; 2018; 18:e179-e185 10.1016/j.clbc.2017.08.001
-
Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer
Cite
Mustafa RE, DeStefano LM, Bahng J, Yoon-Flannery K, Fisher CS, Zhang PJ, et al. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2999-3003 10.1245/s10434-017-5941-0
-
Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?
Cite
Miller ME, Muhsen S, Olcese C, Patil S, Morrow M, Van Zee KJ. Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2889-2897 10.1245/s10434-017-5931-2
-
Active monitoring in non-invasive breast cancer: insight gained from a large national database
Cite
Trifiletti DM, Grover S, Maidment BW, Showalter TN, Showalter SL. Active monitoring in non-invasive breast cancer: insight gained from a large national database. Journal of Radiation Oncology. Springer Science and Business Media LLC; 2017; 6:361-370 10.1007/s13566-017-0322-7
-
Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer
Cite
Luiten JD, Voogd AC, Luiten EJT, Duijm LEM. Trends in incidence and tumour grade in screen-detected ductal carcinoma in situ and invasive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 166:307-314 10.1007/s10549-017-4412-4
-
Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study
Cite
Mullooly M, Khodr ZG, Dallal CM, Nyante SJ, Sherman ME, Falk R, et al. Epidemiologic Risk Factors for In Situ and Invasive Breast Cancers Among Postmenopausal Women in the National Institutes of Health-AARP Diet and Health Study. American Journal of Epidemiology. Oxford University Press (OUP); 2017; 186:1329-1340 10.1093/aje/kwx206
-
Cause-specific mortality in women with breast cancer in situ
Cite
He W, Sofie Lindström L, Hall P, Czene K. Cause-specific mortality in women with breast cancer in situ. International Journal of Cancer. Wiley; 2016; 140:2414-2421 10.1002/ijc.30413
-
The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer
Cite
Nakhlis F, Regan MM, Warren LE, Bellon JR, Hirshfield-Bartek J, Duggan MM, et al. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2017; 24:2563-2569 10.1245/s10434-017-5903-6
-
Breast-Conserving Surgery Alone for Ductal Carcinoma In Situ: Factors Associated with Increased Risk of Local Recurrence
Cite
Mele A, Mehta P, Slanetz PJ, Brook A, Recht A, Sharma R. Breast-Conserving Surgery Alone for Ductal Carcinoma In Situ: Factors Associated with Increased Risk of Local Recurrence. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2016; 24:1221-1226 10.1245/s10434-016-5711-4
-
The true impact of breast magnetic resonance imaging on the management of in situ disease: more is not better
Cite
Lallemand M, Barron M, Bingham J, Mosier A, Hardin M, Sohn V. The true impact of breast magnetic resonance imaging on the management of in situ disease: more is not better. The American Journal of Surgery. Elsevier BV; 2017; 213:127-131 10.1016/j.amjsurg.2016.05.002
-
Plasma carotenoids and the risk of premalignant breast disease in women aged 50 and younger: a nested case–control study
Cite
Cohen K, Liu Y, Luo J, Appleton CM, Colditz GA. Plasma carotenoids and the risk of premalignant breast disease in women aged 50 and younger: a nested case–control study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2017; 162:571-580 10.1007/s10549-017-4152-5
-
Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora’s box
Cite
Lazzeroni M, Dunn BK, Pruneri G, Jereczek-Fossa BA, Orecchia R, Bonanni B, et al. Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora’s box. Cancer Treatment Reviews. Elsevier BV; 2017; 55:1-9 10.1016/j.ctrv.2017.01.010
-
Are We Overtreating Ductal Carcinoma in Situ (DCIS)?
Cite
Khan S, Epstein M, Lagios MD, Silverstein MJ. Are We Overtreating Ductal Carcinoma in Situ (DCIS)?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2016; 24:59-63 10.1245/s10434-016-5501-z
-
Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ
Cite
Mathew J, Karia R, Morgan D, Lee A, Ellis I, Robertson J, et al. Factors influencing local control in patients undergoing breast conservation surgery for ductal carcinoma in situ. The Breast. Elsevier BV; 2017; 31:181-185 10.1016/j.breast.2016.11.002
-
Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program
Cite
Doebar SC, Slaets L, Cardoso F, Giordano SH, Bartlett JM, Tryfonidis K, et al. Male breast cancer precursor lesions: analysis of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Modern Pathology. Springer Science and Business Media LLC; 2017; 30:509-518 10.1038/modpathol.2016.229
-
Health-related behaviors and mortality outcomes in women diagnosed with ductal carcinoma in situ
Cite
Veal CT, Hart V, Lakoski SG, Hampton JM, Gangnon RE, Newcomb PA, et al. Health-related behaviors and mortality outcomes in women diagnosed with ductal carcinoma in situ. Journal of Cancer Survivorship. Springer Science and Business Media LLC; 2017; 11:320-328 10.1007/s11764-016-0590-z
-
Severe fatigue after treatment of ductal carcinoma in situ: A comparison with age-matched breast cancer survivors and healthy controls
Cite
Abrahams H, Smits L, Lugt Md, Roos Wd, Kamm Y, Heins M, et al. Severe fatigue after treatment of ductal carcinoma in situ: A comparison with age-matched breast cancer survivors and healthy controls. The Breast. Elsevier BV; 2017; 31:76-81 10.1016/j.breast.2016.10.020
-
Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy
Cite
van Roozendaal LM, Goorts B, Klinkert M, Keymeulen KBMI, De Vries B, Strobbe LJA, et al. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 156:517-525 10.1007/s10549-016-3783-2
-
The Relationships between HER2 Overexpression and DCIS Characteristics
Cite
Di Cesare P, Pavesi L, Villani L, Battaglia A, Da Prada GA, Riccardi A, et al. The Relationships between HER2 Overexpression and DCIS Characteristics. The Breast Journal. Wiley; 2016; 23:307-314 10.1111/tbj.12735
-
The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden
Cite
Sackey H, Hui M, Czene K, Verkooijen H, Edgren G, Frisell J, et al. The impact of in situ breast cancer and family history on risk of subsequent breast cancer events and mortality - a population-based study from Sweden. Breast Cancer Research. Springer Science and Business Media LLC; 2016; 18 10.1186/s13058-016-0764-7
-
Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race
Cite
Madubata CC, Liu Y, Goodman MS, Yun S, Yu J, Lian M, et al. Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 160:563-572 10.1007/s10549-016-4030-6
-
Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?
Cite
Pilewskie M, Stempel M, Rosenfeld H, Eaton A, Van Zee KJ, Morrow M. Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2016; 23:3487-3493 10.1245/s10434-016-5268-2
-
Cause-specific mortality in women with breast cancerin situ
Cite
He W, Sofie Lindström L, Hall P, Czene K. Cause-specific mortality in women with breast cancerin situ. International Journal of Cancer. Wiley; 2016; 140:2414-2421 10.1002/ijc.30413
-
Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy
Cite
Menes TS, Kerlikowske K, Lange J, Jaffer S, Rosenberg R, Miglioretti DL. Subsequent Breast Cancer Risk Following Diagnosis of Atypical Ductal Hyperplasia on Needle Biopsy. JAMA Oncology. American Medical Association (AMA); 2017; 3:36 10.1001/jamaoncol.2016.3022
-
In situ clinical evidence that zinc levels are decreased in breast invasive ductal carcinoma
Cite
Costello LC, Zou J, Franklin RB. In situ clinical evidence that zinc levels are decreased in breast invasive ductal carcinoma. Cancer Causes & Control. Springer Science and Business Media LLC; 2016; 27:729-735 10.1007/s10552-016-0746-1
-
Different Biological Action of Oleic Acid in ALDHhigh and ALDHlow Subpopulations Separated from Ductal Carcinoma In Situ of Breast Cancer
Cite
Kim HS, Jung M, Choi SK, Moon WK, Kim SJ. Different Biological Action of Oleic Acid in ALDHhigh and ALDHlow Subpopulations Separated from Ductal Carcinoma In Situ of Breast Cancer. PLOS ONE. Public Library of Science (PLoS); 2016; 11:e0160835 10.1371/journal.pone.0160835
-
Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women
Cite
Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J. Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 159:553-563 10.1007/s10549-016-3973-y
-
Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial
Cite
Vrieling C, van Werkhoven E, Maingon P, Poortmans P, Weltens C, Fourquet A, et al. Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial. JAMA Oncology. American Medical Association (AMA); 2017; 3:42 10.1001/jamaoncol.2016.3031
-
Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013
Cite
Thomas A, Weigel RJ, Lynch CF, Spanheimer PM, Breitbach EK, Schroeder MC. Incidence, characteristics, and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000 to 2013. The American Journal of Surgery. Elsevier BV; 2017; 214:323-328 10.1016/j.amjsurg.2016.08.008
-
Management of Ductal Carcinoma In Situ of the Breast
Cite
Shah C, Wobb J, Manyam B, Kundu N, Arthur D, Wazer D, et al. Management of Ductal Carcinoma In Situ of the Breast. JAMA Oncology. American Medical Association (AMA); 2016; 2:1083 10.1001/jamaoncol.2016.0525
-
Association of Locoregional Control With High Body Mass Index in Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer
Cite
Bergom C, Kelly T, Bedi M, Saeed H, Prior P, Rein LE, et al. Association of Locoregional Control With High Body Mass Index in Women Undergoing Breast Conservation Therapy for Early-Stage Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2016; 96:65-71 10.1016/j.ijrobp.2016.04.020
-
Impact of a prior diagnosis of DCIS on survival from invasive breast cancer
Cite
Sopik V, Iqbal J, Sun P, Narod SA. Impact of a prior diagnosis of DCIS on survival from invasive breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 158:385-393 10.1007/s10549-016-3894-9
-
Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study
Cite
Doebar SC, van den Broek EC, Koppert LB, Jager A, Baaijens MHA, Obdeijn IAM, et al. Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2016; 158:179-187 10.1007/s10549-016-3862-4
-
Emerging trends in surgical and adjuvant radiation therapies among women diagnosed with ductal carcinoma in situ
Cite
Shiyanbola OO, Sprague BL, Hampton JM, Dittus K, James TA, Herschorn S, et al. Emerging trends in surgical and adjuvant radiation therapies among women diagnosed with ductal carcinoma in situ. Cancer. Wiley; 2016; 122:2810-2818 10.1002/cncr.30105
-
Weight loss reduces basal-like breast cancer through kinome reprogramming
Cite
Qin Y, Sundaram S, Essaid L, Chen X, Miller SM, Yan F, et al. Weight loss reduces basal-like breast cancer through kinome reprogramming. Cancer Cell International. Springer Science and Business Media LLC; 2016; 16 10.1186/s12935-016-0300-y
-
Abstract 2576: Radiation therapy delay and risk of ipsilateral breast tumors in women with ductal carcinomain situ
Cite
Liu Y, Yun S, Lian M, Colditz G. Abstract 2576: Radiation therapy delay and risk of ipsilateral breast tumors in women with ductal carcinomain situ. Epidemiology. American Association for Cancer Research; 2016; 10.1158/1538-7445.am2016-2576
-
CD 8 + tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER 2‐positive ductal carcinoma in situ
Cite
Morita M, Yamaguchi R, Tanaka M, Tse GM, Yamaguchi M, Kanomata N, et al. CD 8 + tumor‐infiltrating lymphocytes contribute to spontaneous “healing” in HER 2‐positive ductal carcinoma in situ. Cancer Medicine. Wiley; 2016; 5:1607-1618 10.1002/cam4.715
-
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial
Cite
Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, et al. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. The Lancet. Elsevier BV; 2016; 387:849-856 10.1016/s0140-6736(15)01168-x
-
Epidemiologic evidence of slow growing, nonprogressive or regressive breast cancer: A systematic review
Cite
Segnan N, Minozzi S, Armaroli P, Cinquini M, Bellisario C, González-Lorenzo M, et al. Epidemiologic evidence of slow growing, nonprogressive or regressive breast cancer: A systematic review. International Journal of Cancer. Wiley; 2016; 139:554-573 10.1002/ijc.30105
-
The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study
Cite
Borgquist S, Zhou W, Jirström K, Amini R, Sollie T, Sørlie T, et al. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study. BMC Cancer. Springer Science and Business Media LLC; 2015; 15 10.1186/s12885-015-1479-3
-
Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study
Cite
Sagara Y, Freedman RA, Vaz-Luis I, Mallory MA, Wong SM, Aydogan F, et al. Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast-Conserving Surgery for Ductal Carcinoma In Situ: A Population-Based Longitudinal Cohort Study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016; 34:1190-1196 10.1200/jco.2015.65.1869
-
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ
Cite
Worni M, Akushevich I, Greenup R, Sarma D, Ryser MD, Myers ER, et al. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 107:djv263 10.1093/jnci/djv263
-
Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ
Cite
Clements K, Dodwell D, Lawrence G, Ball G, Francis A, Pinder S, et al. Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2015; 41:1406-1410 10.1016/j.ejso.2015.07.021
-
Hypofractionated versus conventionally fractionated radiotherapy for ductal carcinoma in situ (DCIS) of the breast
Cite
Oar AJ, Boxer MM, Papadatos G, Delaney GP, Phan P, Descallar J, et al. Hypofractionated versus conventionally fractionated radiotherapy for ductal carcinoma in situ (DCIS) of the breast. Journal of Medical Imaging and Radiation Oncology. Wiley; 2016; 60:407-413 10.1111/1754-9485.12428
-
The relationship between local recurrence and death in early-stage breast cancer
Cite
Sopik V, Nofech-Mozes S, Sun P, Narod SA. The relationship between local recurrence and death in early-stage breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2015; 155:175-185 10.1007/s10549-015-3666-y
-
Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies
Cite
Renshaw AA, Gould EW. Long term clinical follow-up of atypical ductal hyperplasia and lobular carcinoma in situ in breast core needle biopsies. Pathology. Elsevier BV; 2016; 48:25-29 10.1016/j.pathol.2015.11.015
-
Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis
Cite
Ryser MD, Worni M, Turner EL, Marks JR, Durrett R, Hwang ES. Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. Journal of the National Cancer Institute. Oxford University Press (OUP); 2015; 108:djv372 10.1093/jnci/djv372
-
Breast screening interval and the characteristics of screen-detected cancers
Cite
Tupper CA, Maxwell AJ, Astley S, Bydder M, Gadde S, Harkness E, et al. Breast screening interval and the characteristics of screen-detected cancers. Breast Cancer Research. Springer Science and Business Media LLC; 2015; 17 10.1186/bcr3758
-
Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study
Cite
Duffy SW, Dibden A, Michalopoulos D, Offman J, Parmar D, Jenkins J, et al. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. The Lancet Oncology. Elsevier BV; 2016; 17:109-114 10.1016/s1470-2045(15)00446-5
-
Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis
Cite
Stuart KE, Houssami N, Taylor R, Hayen A, Boyages J. Long-term outcomes of ductal carcinoma in situ of the breast: a systematic review, meta-analysis and meta-regression analysis. BMC Cancer. Springer Science and Business Media LLC; 2015; 15 10.1186/s12885-015-1904-7
-
Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
Cite
Poulakaki N, Makris G, Battista M, Böhm D, Petraki K, Bafaloukos D, et al. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?. The Breast. Elsevier BV; 2016; 25:57-61 10.1016/j.breast.2015.10.007
-
Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base
Cite
Flanagan MR, Rendi MH, Gadi VK, Calhoun KE, Gow KW, Javid SH. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2015; 22:3264-3272 10.1245/s10434-015-4668-z
-
Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ
Cite
Van Zee KJ, Subhedar P, Olcese C, Patil S, Morrow M. Relationship Between Margin Width and Recurrence of Ductal Carcinoma In Situ. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2015; 262:623-631 10.1097/sla.0000000000001454
-
Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast biopsies
Cite
Zhang Z, Atwell LL, Farris PE, Ho E, Shannon J. Associations between cruciferous vegetable intake and selected biomarkers among women scheduled for breast biopsies. Public Health Nutrition. Cambridge University Press (CUP); 2015; 19:1288-1295 10.1017/s136898001500244x
-
Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ
Cite
Davis JE, Nemesure B, Mehmood S, Nayi V, Burke S, Brzostek SR, et al. Her2 and Ki67 Biomarkers Predict Recurrence of Ductal Carcinoma in Situ. Applied Immunohistochemistry & Molecular Morphology. Ovid Technologies (Wolters Kluwer Health); 2016; 24:20-25 10.1097/pai.0000000000000223
-
Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ
Cite
Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncology. American Medical Association (AMA); 2015; 1:888 10.1001/jamaoncol.2015.2510
-
Role of Androgen and Estrogen Receptors as Prognostic and Potential Predictive Markers of Ductal Carcinoma in Situ of the Breast
Cite
Tumedei MM, Silvestrini R, Ravaioli S, Massa I, Maltoni R, Rocca A, et al. Role of Androgen and Estrogen Receptors as Prognostic and Potential Predictive Markers of Ductal Carcinoma in Situ of the Breast. The International Journal of Biological Markers. SAGE Publications; 2015; 30:425-428 10.5301/jbm.5000163
-
Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ
Cite
Sagara Y, Mallory MA, Wong S, Aydogan F, DeSantis S, Barry WT, et al. Survival Benefit of Breast Surgery for Low-Grade Ductal Carcinoma In Situ. JAMA Surgery. American Medical Association (AMA); 2015; 150:739 10.1001/jamasurg.2015.0876
-
Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases
Cite
Cutuli B, De Lafontan B, Kirova Y, Auvray H, Tallet A, Avigdor S, et al. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases. Radiation Oncology. Springer Science and Business Media LLC; 2015; 10 10.1186/s13014-015-0379-7
-
Abstract P6-13-06: Tamoxifen acceptance by DCIS patients and effect on subsequent ipsilateral and contralateral breast events
Cite
Higham AM, Helenowski IB, Zaveri SR, Schneider DH, Hansen NM, Bethke KP, et al. Abstract P6-13-06: Tamoxifen acceptance by DCIS patients and effect on subsequent ipsilateral and contralateral breast events. Poster Session Abstracts. American Association for Cancer Research; 2015; 10.1158/1538-7445.sabcs14-p6-13-06
-
Risk of subsequentin situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinomain situ
Cite
Curigliano G, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, et al. Risk of subsequentin situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinomain situ. Annals of Oncology. Elsevier BV; 2015; 26:682-687 10.1093/annonc/mdv013
-
Sulforaphane inhibited tumor necrosis factor-α induced migration and invasion in estrogen receptor negative human breast cancer cells
Cite
Bao C, Ko J, Park H, Kim MC, Kim J, Auh J, et al. Sulforaphane inhibited tumor necrosis factor-α induced migration and invasion in estrogen receptor negative human breast cancer cells. Food Science and Biotechnology. Springer Science and Business Media LLC; 2015; 24:347-351 10.1007/s10068-015-0046-7
-
Racial differences in breast cancer, cardiovascular disease, and all-cause mortality among women with ductal carcinoma in situ of the breast
Cite
Berkman A, F. Cole B, Ades PA, Dickey S, Higgins ST, Trentham-Dietz A, et al. Racial differences in breast cancer, cardiovascular disease, and all-cause mortality among women with ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2014; 148:407-413 10.1007/s10549-014-3168-3
-
Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis
Cite
Staley H, McCallum I, Bruce J. Postoperative Tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. The Breast. Elsevier BV; 2014; 23:546-551 10.1016/j.breast.2014.06.015
-
Cardiovascular Morbidity and Mortality After Treatment for Ductal Carcinoma In Situ of the Breast
Cite
Boekel NB, Schaapveld M, Gietema JA, Rutgers EJT, Versteegh MIM, Visser O, et al. Cardiovascular Morbidity and Mortality After Treatment for Ductal Carcinoma In Situ of the Breast. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2014; 106 10.1093/jnci/dju156
-
Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival
Cite
Dieterich M, Hartwig F, Stubert J, Klöcking S, Kundt G, Stengel B, et al. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. The Breast. Elsevier BV; 2014; 23:346-351 10.1016/j.breast.2014.01.015
-
Is carcinomain situa precursor lesion of invasive breast cancer?
Cite
To T, Wall C, Baines CJ, Miller AB. Is carcinomain situa precursor lesion of invasive breast cancer?. International Journal of Cancer. Wiley; 2014; 135:1646-1652 10.1002/ijc.28803
-
Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial
Cite
Donker M, Litière S, Werutsky G, Julien J, Fentiman IS, Agresti R, et al. Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2013; 31:4054-4059 10.1200/jco.2013.49.5077
-
Post-operative radiotherapy for ductal carcinoma in situ of the breast
Cite
Goodwin A, Parker S, Ghersi D, Wilcken N. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database of Systematic Reviews. Wiley; 2013; 10.1002/14651858.cd000563.pub7
-
Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study
Cite
Sprague BL, McLaughlin V, Hampton JM, Newcomb PA, Trentham-Dietz A. Disease-free survival by treatment after a DCIS diagnosis in a population-based cohort study. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2013; 141:145-154 10.1007/s10549-013-2670-3
-
Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery
Cite
Benson JR, Wishart GC. Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. The Lancet Oncology. Elsevier BV; 2013; 14:e348-e357 10.1016/s1470-2045(13)70135-9
-
Long-Term Impact of Young Age at Diagnosis on Treatment Outcome and Patterns of Failure in Patients with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy
Cite
Vicini FA, Shaitelman S, Wilkinson JB, Shah C, Ye H, Kestin LL, et al. Long-Term Impact of Young Age at Diagnosis on Treatment Outcome and Patterns of Failure in Patients with Ductal Carcinoma In Situ Treated with Breast-Conserving Therapy. The Breast Journal. Wiley; 2013; 19:365-373 10.1111/tbj.12127
-
Modeling the Effectiveness of Initial Management Strategies for Ductal Carcinoma In Situ
Cite
Soeteman DI, Stout NK, Ozanne EM, Greenberg C, Hassett MJ, Schrag D, et al. Modeling the Effectiveness of Initial Management Strategies for Ductal Carcinoma In Situ. JNCI: Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:774-781 10.1093/jnci/djt096
-
A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast
Cite
Solin LJ, Gray R, Baehner FL, Butler SM, Hughes LL, Yoshizawa C, et al. A Multigene Expression Assay to Predict Local Recurrence Risk for Ductal Carcinoma In Situ of the Breast. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2013; 105:701-710 10.1093/jnci/djt067
-
Selective use of whole breast radiotherapy after breast conserving surgery for invasive breast cancer and DCIS
Cite
Skandarajah AR, Bruce Mann G. Selective use of whole breast radiotherapy after breast conserving surgery for invasive breast cancer and DCIS. The Surgeon. Elsevier BV; 2013; 11:278-285 10.1016/j.surge.2013.03.005
-
Lifestyle Factors and the Risk of a Second Breast Diagnosis after DCIS in the Wisconsin In Situ Cohort
Cite
V M, A T, JM H, PA N, BL S. Lifestyle Factors and the Risk of a Second Breast Diagnosis after DCIS in the Wisconsin In Situ Cohort. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2013; 22:472.1-472 10.1158/1055-9965.epi-13-0065
-
Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis
Cite
Rakovitch E, Nofech-Mozes S, Narod SA, Hanna W, Thiruchelvam D, Saskin R, et al. Can we select individuals with low risk ductal carcinoma in situ (DCIS)? A population-based outcomes analysis. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2013; 138:581-590 10.1007/s10549-013-2455-8
-
Outcomes in Patients Treated With Mastectomy for Ductal Carcinoma In Situ
Cite
Owen D, Tyldesley S, Alexander C, Speers C, Truong P, Nichol A, et al. Outcomes in Patients Treated With Mastectomy for Ductal Carcinoma In Situ. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2013; 85:e129-e134 10.1016/j.ijrobp.2012.10.020
-
Therapeutic Mammaplasty for Breast Cancer: Oncological and Aesthetic Outcomes
Cite
Grubnik A, Benn C, Edwards G. Therapeutic Mammaplasty for Breast Cancer: Oncological and Aesthetic Outcomes. World Journal of Surgery. Springer Science and Business Media LLC; 2012; 37:72-83 10.1007/s00268-012-1786-7
-
The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS
Cite
Wallis MG, Clements K, Kearins O, Ball G, Macartney J, Lawrence GM. The effect of DCIS grade on rate, type and time to recurrence after 15 years of follow-up of screen-detected DCIS. British Journal of Cancer. Springer Science and Business Media LLC; 2012; 106:1611-1617 10.1038/bjc.2012.151
-
Twenty-Year Outcomes after Breast-Conserving Surgery and Definitive Radiotherapy for Mammographically Detected Ductal Carcinoma In Situ
Cite
Wilkinson JB, Vicini FA, Shah C, Shaitelman S, Jawad MS, Ye H, et al. Twenty-Year Outcomes after Breast-Conserving Surgery and Definitive Radiotherapy for Mammographically Detected Ductal Carcinoma In Situ. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2012; 19:3785-3791 10.1245/s10434-012-2412-5
-
Biology, Treatment, and Outcome in Very Young and Older Women with DCIS
Cite
Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, et al. Biology, Treatment, and Outcome in Very Young and Older Women with DCIS. Annals of Surgical Oncology. Springer Science and Business Media LLC; 2012; 19:3777-3784 10.1245/s10434-012-2413-4
-
Nonsurgical Management of High-Risk Lesions Diagnosed at Core Needle Biopsy: Can Malignancy Be Ruled Out Safely With Breast MRI?
Cite
Linda A, Zuiani C, Furlan A, Lorenzon M, Londero V, Girometti R, et al. Nonsurgical Management of High-Risk Lesions Diagnosed at Core Needle Biopsy: Can Malignancy Be Ruled Out Safely With Breast MRI?. American Journal of Roentgenology. American Roentgen Ray Society; 2012; 198:272-280 10.2214/ajr.11.7040
-
Ten-Year Risk of Diagnostic Mammograms and Invasive Breast Procedures After Breast-Conserving Surgery for DCIS
Cite
Nekhlyudov L, Habel LA, Achacoso N, Jung I, Haque R, Collins LC, et al. Ten-Year Risk of Diagnostic Mammograms and Invasive Breast Procedures After Breast-Conserving Surgery for DCIS. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2012; 104:614-621 10.1093/jnci/djs167
-
Long-Term Outcome in Patients With Ductal Carcinoma In Situ Treated With Breast-Conserving Therapy: Implications for Optimal Follow-up Strategies
Cite
Shaitelman SF, Wilkinson JB, Kestin LL, Ye H, Goldstein NS, Martinez AA, et al. Long-Term Outcome in Patients With Ductal Carcinoma In Situ Treated With Breast-Conserving Therapy: Implications for Optimal Follow-up Strategies. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2012; 83:e305-e312 10.1016/j.ijrobp.2011.12.092
-
Accuracy and Completeness of Pathology Reporting — Impact on Partial Breast Irradiation Eligibility
Cite
Pignol J, Rakovitch E, Zeppieri J, Hanna W. Accuracy and Completeness of Pathology Reporting — Impact on Partial Breast Irradiation Eligibility. Clinical Oncology. Elsevier BV; 2012; 24:177-182 10.1016/j.clon.2011.09.004
-
Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence
Cite
Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, et al. Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence. Clinical Oncology. Elsevier BV; 2012; 24:183-189 10.1016/j.clon.2011.09.008
-
HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
Cite
Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. British Journal of Cancer. Springer Science and Business Media LLC; 2012; 106:1160-1165 10.1038/bjc.2012.41
-
Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer
Cite
Mangé A, Lacombe J, Bascoul-Mollevi C, Jarlier M, Lamy P, Rouanet P, et al. Serum Autoantibody Signature of Ductal Carcinoma In Situ Progression to Invasive Breast Cancer. Clinical Cancer Research. American Association for Cancer Research (AACR); 2012; 18:1992-2000 10.1158/1078-0432.ccr-11-2527
-
Accelerated partial breast irradiation using once-daily fractionation: analysis of 312 cases with four years median follow-up
Cite
Shaikh AY, LaCombe MA, Du H, Raghavan VT, Nanda RK, Bloomer WD. Accelerated partial breast irradiation using once-daily fractionation: analysis of 312 cases with four years median follow-up. Radiation Oncology. Springer Science and Business Media LLC; 2012; 7 10.1186/1748-717x-7-17
-
Improved Outcomes of Breast-Conserving Therapy for Patients With Ductal Carcinoma in Situ
Cite
Halasz LM, Sreedhara M, Chen Y, Bellon JR, Punglia RS, Wong JS, et al. Improved Outcomes of Breast-Conserving Therapy for Patients With Ductal Carcinoma in Situ. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2012; 82:e581-e586 10.1016/j.ijrobp.2011.08.015
-
Ductal Carcinoma In Situ With Microinvasion: Prognostic Implications, Long-Term Outcomes, and Role of Axillary Evaluation
Cite
Parikh RR, Haffty BG, Lannin D, Moran MS. Ductal Carcinoma In Situ With Microinvasion: Prognostic Implications, Long-Term Outcomes, and Role of Axillary Evaluation. International Journal of Radiation Oncology*Biology*Physics. Elsevier BV; 2012; 82:7-13 10.1016/j.ijrobp.2010.08.027
-
S4-6: A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194.
Cite
Solin L, Gray R, Baehner F, Butler S, Badve S, Yoshizawa C, et al. S4-6: A Quantitative Multigene RT-PCR Assay for Predicting Recurrence Risk after Surgical Excision Alone without Irradiation for Ductal Carcinoma In Situ (DCIS): A Prospective Validation Study of the DCIS Score from ECOG E5194.. General Session Abstracts. American Association for Cancer Research; 2011; 10.1158/0008-5472.sabcs11-s4-6
-
Should palpable DCIS be treated as IDC? A retrospective audit.
Cite
Nair NS, Pandey N, Vanmali V, Shet T, Hawaldar R, Parmar V, et al. Should palpable DCIS be treated as IDC? A retrospective audit.. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:146-146 10.1200/jco.2011.29.27_suppl.146
-
Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer
Cite
Wong H, Lau S, Leung R, Chiu J, Cheung P, Wong TT, et al. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer. Medical Oncology. Springer Science and Business Media LLC; 2011; 29:1536-1542 10.1007/s12032-011-0082-y
-
Axillary node staging for microinvasive breast cancer: Is it justified?
Cite
Lyons JM, Stempel M, Van Zee KJ, Cody HS. Axillary node staging for microinvasive breast cancer: Is it justified?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2011; 29:7-7 10.1200/jco.2011.29.27_suppl.7
-
Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?
Cite
Yerushalmi R, Tyldesley S, Woods R, Kennecke H, Speers C, Gelmon K. Is breast-conserving therapy a safe option for patients with tumor multicentricity and multifocality?. Annals of Oncology. Elsevier BV; 2011; 23:876-881 10.1093/annonc/mdr326
-
Mammographic Breast Density and Subsequent Risk of Breast Cancer in Postmenopausal Women According to Tumor Characteristics
Cite
Yaghjyan L, Colditz GA, Collins LC, Schnitt SJ, Rosner B, Vachon C, et al. Mammographic Breast Density and Subsequent Risk of Breast Cancer in Postmenopausal Women According to Tumor Characteristics. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:1179-1189 10.1093/jnci/djr225
-
Dietary Glycemic Load, Glycemic Index, and Carbohydrate and Risk of Breast Cancer in the Women's Health Initiative
Cite
Shikany JM, Redden DT, Neuhouser ML, Chlebowski RT, Rohan TE, Simon MS, et al. Dietary Glycemic Load, Glycemic Index, and Carbohydrate and Risk of Breast Cancer in the Women's Health Initiative. Nutrition and Cancer. Informa UK Limited; 2011; 63:899-907 10.1080/01635581.2011.587227
-
Breast cancer multifocality, disease extent, and survival
Cite
Tot T, Gere M, Pekár G, Tarján M, Hofmeyer S, Hellberg D, et al. Breast cancer multifocality, disease extent, and survival. Human Pathology. Elsevier BV; 2011; 42:1761-1769 10.1016/j.humpath.2011.02.002
-
The Association between Prognostic Demographic and Tumor Characteristics of Breast Carcinomas with Serum 25-OH Vitamin D Levels
Cite
Peppone L, Rickles A, Huston A, Sprod L, Hicks D, Mustian K, et al. The Association between Prognostic Demographic and Tumor Characteristics of Breast Carcinomas with Serum 25-OH Vitamin D Levels. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2011; 20:717.2-717 10.1158/1055-9965.epi-11-0089
-
Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS
Cite
Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, et al. Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:478-488 10.1093/jnci/djr027
-
Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: A comparison with ECOG study 5194
Cite
Motwani SB, Goyal S, Moran MS, Chhabra A, Haffty BG. Ductal carcinoma in situ treated with breast-conserving surgery and radiotherapy: A comparison with ECOG study 5194. Cancer. Wiley; 2010; 117:1156-1162 10.1002/cncr.25623
-
Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A review
Cite
Hussain M, Cunnick G. Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A review. European Journal of Surgical Oncology (EJSO). Elsevier BV; 2011; 37:279-289 10.1016/j.ejso.2011.01.009
-
Comparative Effectiveness of Ductal Carcinoma In Situ Management and the Roles of Margins and Surgeons
Cite
Dick AW, Sorbero MS, Ahrendt GM, Hayman JA, Gold HT, Schiffhauer L, et al. Comparative Effectiveness of Ductal Carcinoma In Situ Management and the Roles of Margins and Surgeons. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2011; 103:92-104 10.1093/jnci/djq499
-
A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression
Cite
Ough M, Velasco J, Hieken TJ. A comparative analysis of core needle biopsy and final excision for breast cancer: histology and marker expression. The American Journal of Surgery. Elsevier BV; 2011; 201:692-694 10.1016/j.amjsurg.2010.02.015
-
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial
Cite
Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. The Lancet Oncology. Elsevier BV; 2011; 12:21-29 10.1016/s1470-2045(10)70266-7
-
Risk Factors for Invasive Breast Cancer When Core Needle Biopsy Shows Ductal Carcinoma In Situ
Cite
Kurniawan ED. Risk Factors for Invasive Breast Cancer When Core Needle Biopsy Shows Ductal Carcinoma In Situ. Archives of Surgery. American Medical Association (AMA); 2010; 145:1098 10.1001/archsurg.2010.243
-
Mammographic Density and Risk of Second Breast Cancer after Ductal Carcinoma In situ
Cite
Habel LA, Capra AM, Achacoso NS, Janga A, Acton L, Puligandla B, et al. Mammographic Density and Risk of Second Breast Cancer after Ductal Carcinoma In situ. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:2488-2495 10.1158/1055-9965.epi-10-0769
-
Alcohol Consumption and Risk of Ductal Carcinoma In situ of the Breast in a Cohort of Postmenopausal Women
Cite
Kabat GC, Kim M, Shikany JM, Rodgers AK, Wactawski-Wende J, Lane D, et al. Alcohol Consumption and Risk of Ductal Carcinoma In situ of the Breast in a Cohort of Postmenopausal Women. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2010; 19:2066-2072 10.1158/1055-9965.epi-10-0388
-
Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer
Cite
Buist DSM, Abraham LA, Barlow WE, Krishnaraj A, Holdridge RC, Sickles EA, et al. Diagnosis of second breast cancer events after initial diagnosis of early stage breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2010; 124:863-873 10.1007/s10549-010-1106-6
-
Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter?
Cite
Muhsen S, Morrogh M, Andrade AP, Sakr R, Paik W, Morrow M, et al. Risk for subsequent breast cancer after lobular carcinoma in situ: Do clinical factors matter?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1593-1593 10.1200/jco.2010.28.15_suppl.1593
-
Determination of clear margin in breast-conserving surgery: Is 1 mm needed?
Cite
Geffrelot J, Toudic Emily F, Levy C, Blanc Fournier C, Segura C, Switsers O, et al. Determination of clear margin in breast-conserving surgery: Is 1 mm needed?. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:515-515 10.1200/jco.2010.28.15_suppl.515
-
Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer
Cite
Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. British Journal of Cancer. Springer Science and Business Media LLC; 2010; 102:1391-1396 10.1038/sj.bjc.6605655
-
Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis
Cite
Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, et al. Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:627-637 10.1093/jnci/djq101
-
The Influence of Margin Width and Volume of Disease Near Margin on Benefit of Radiation Therapy for Women With DCIS Treated With Breast-Conserving Therapy
Cite
Rudloff U, Brogi E, Reiner AS, Goldberg JI, Brockway JP, Wynveen CA, et al. The Influence of Margin Width and Volume of Disease Near Margin on Benefit of Radiation Therapy for Women With DCIS Treated With Breast-Conserving Therapy. Annals of Surgery. Ovid Technologies (Wolters Kluwer Health); 2010; 251:583-591 10.1097/sla.0b013e3181b5931e
-
The Use of Oncoplastic Reduction Techniques to Reconstruct Partial Mastectomy Defects in Women with Ductal Carcinoma In Situ
Cite
Song HM, Styblo TM, Carlson GW, Losken A. The Use of Oncoplastic Reduction Techniques to Reconstruct Partial Mastectomy Defects in Women with Ductal Carcinoma In Situ. The Breast Journal. Wiley; 2010; 16:141-146 10.1111/j.1524-4741.2009.00891.x
-
Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial
Cite
Kuhl C, Weigel S, Schrading S, Arand B, Bieling H, König R, et al. Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010; 28:1450-1457 10.1200/jco.2009.23.0839
-
Cyclooxygenase-2 Inhibition for the Prophylaxis and Treatment of Preinvasive Breast Cancer in a Her-2/Neu Mouse Model
Cite
Tran-Thanh D, Buttars S, Wen Y, Wilson C, Done SJ. Cyclooxygenase-2 Inhibition for the Prophylaxis and Treatment of Preinvasive Breast Cancer in a Her-2/Neu Mouse Model. Cancer Prevention Research. American Association for Cancer Research (AACR); 2010; 3:202-211 10.1158/1940-6207.capr-09-0181
-
Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes
Cite
Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal Carcinoma In Situ of the Breast: A Systematic Review of Incidence, Treatment, and Outcomes. JNCI Journal of the National Cancer Institute. Oxford University Press (OUP); 2010; 102:170-178 10.1093/jnci/djp482
-
Risk of needle tract seeding of breast cancer: cytological results derived from core wash material
Cite
Uematsu T, Kasami M. Risk of needle tract seeding of breast cancer: cytological results derived from core wash material. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2007; 110:51-55 10.1007/s10549-007-9685-6
-
Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies
Cite
Jardé T, Caldefie-Chézet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocrine-Related Cancer. Bioscientifica; 2009; 16:1197-1210 10.1677/erc-09-0043
-
The association of metabolic syndrome with triple-negative breast cancer
Cite
Maiti B, Kundranda MN, Spiro TP, Daw HA. The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2009; 121:479-483 10.1007/s10549-009-0591-y
-
Factors predicting in-breast tumor recurrence after breast-conserving surgery
Cite
Mechera R, Viehl CT, Oertli D. Factors predicting in-breast tumor recurrence after breast-conserving surgery. Breast Cancer Research and Treatment. Springer Science and Business Media LLC; 2008; 116:171-177 10.1007/s10549-008-0187-y
-
Tea Consumption and Risk of Breast Cancer
Cite
Kumar N, Titus-Ernstoff L, Newcomb PA, Trentham-Dietz A, Anic G, Egan KM. Tea Consumption and Risk of Breast Cancer. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:341-345 10.1158/1055-9965.epi-08-0819
-
The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004
Cite
Eheman CR, Shaw KM, Ryerson AB, Miller JW, Ajani UA, White MC. The Changing Incidence of In situ and Invasive Ductal and Lobular Breast Carcinomas: United States, 1999-2004. Cancer Epidemiology Biomarkers & Prevention. American Association for Cancer Research (AACR); 2009; 18:1763-1769 10.1158/1055-9965.epi-08-1082